I think this is a good move by management because it should reduce short term volatility in the stock. Institutional shareholders generally don't like short term volatility and I think it's a reason there are so few instos on the register for what is now a $1bn+ market cap stock (the relatively low liquidity has also kept the instos away, although that it starting to improve).
- Forums
- ASX - By Stock
- SRX
- No more 1/4 dose sales
No more 1/4 dose sales, page-10
Featured News
Add SRX (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
BTH
BIGTINCAN HOLDINGS LIMITED
David Keane, Co-Founder & CEO
David Keane
Co-Founder & CEO
Previous Video
Next Video
SPONSORED BY The Market Online